	E V	, .		() }}	-09-0) (
3	₽	Please type a plus sign (+) inside this box		<i>O</i> ,	, 0		
8	C.	UTILITY	Attorney Docket No.		ORT-1453		
^ 	S.	PATENT APPLICATION	First Inventor		Carlos Plata-Sa	laman	
	PTO	TRANSMITTAL	Title		PREVENTING T MELLITUS AND	ANT DERIVATIVES USEFUL FOR THE DEVELOPMENT OF TYPE II DIABETES SYNDROME X	;
	(only for new nonprovisional applications under 37 CFR 1 53(b))	Express Mail La	bel No.	EL457891481US	3	
		APPLICATION ELEMENTS		ADD	RESS TO:	Commissioner for Patents	
	COL	e MPEP Chapter 600 concerning utility patent appliants.				Box Patent Application Washington, DC 20231	
	1.	Fee Transmittal Form (e.g., PTO) (submit an original and a duplicate for fee p Applicant claims small entity state	rocessing)	7 Com	CD-ROM or puter Progra	CD-R in duplicate, large table or m (Appendix)	
		3. Specification [Total Pages 28] (Preferred arrangement set forth below)			8. Nucleotide and/or Amino Acid Sequence		
	<u>.</u>	 Descriptive Title of the Invention 		a □(Submission (it	f applicable, all necessary) dable Form (CRF)	
	ý	Cross Reference to Related ApplicaStatement Regarding Fed sponsore	ations	b.□\$	Specification S	equence Listing on:	
		 Reference to sequence listing, a tal 	ole, or a		i.	or CD-R (2 copies); or	
	computer program listing appendix - Background of the Invention			c. Statement verifying identity of above copies volume			
		- Brief Summary of the Invention				YING APPLICATION PARTS	7
		 Brief Description of the Drawings (if Detailed Description 	filed)	10.	37 CFR 3.73	Papers (cover sheet & document(s)) 8(b) Statement Power of Attorney	,
- F		- Claim(s)			(when there i.	s an assignee)	١
100m 100m 100m		- Abstract of the Disclosure		12 _	ngiish Trans. formation D.	slation Document (if applicable) Disclosure Statement	
	4. Drawing(s)(35 USC 113) [Total Sheets] 5. Oath or Declaration [Total Pages]			(IDS)/PTO-1449			3
	3.	Oath or Declaration	ages j pv)	13.	Return Recei	mendment pt Postcard (MPEP 503)	I
Ţ		b. Copy from a prior application (37 CFR 1.63(d))			(Should be specifically itemized)		
£		(for continuation/divisional with Box 18 i. ☐ DELETION OF INVENTOR(S	completed)	15	Certified Copy	y of Priority Document(s) rity is claimed)	l
2000 2000 2000 2000 2000 2000 2000 200	Signed statement attached deleting				Request and	Certifications under 35 U.S.C. 122	-
*****		inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).			(b)(2)(B)(i). A	Applicant must attach form or its equivalent.	1
		000 01 01 11 1.00(d)(2) and 1.	33(b).	17. 🗆		its equivalent.	
¥	6.	Application Data Sheet. See 37 C	FR 1.76				
18. If a CONTINUING APPLICATION, check appropriate box and sup				oply the requisite	e information below and in a	\dashv	
		preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) of prior application No.:					
	Prid	Prior application information: Examiner Group Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an path or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.					
	oat						
	con						
	relie						
	19. CORRESPONDENCE ADDRESS						

☐ Customer Number or Bar Code Label 000027777 or ☐ Correspondence Address below

20. TELEPHONE CONTACT

Reg. No. 29486

Fax: (732) 524-2808 21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Philip S. Johnson, Esq.

Raiph R. Falg

July 6, 2001

One Johnson & Johnson Plaza

New Brunswick, NJ 08933-7003 USA

Please direct all telephone calls or telefaxes to Ralph R. Palo at:

Johnson & Johnson

(732) 524-2818

Name: Address:

Telephone:

SIGNATURE

NAME

DATE

	Complete if Known			
	Application Number			
FEE TRANSMITTAL	Filing Date	July 6, 2001		
	First Named Inventor	Carlos Plata-Salaman		
	Group Art Unit			
	Examiner Name			
	Attorney Docket Number	ORT-1453		

FEE CALCULATION

CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$710.00
TOTAL CLAIMS	24 - 20 =	4	x 18.00	\$ 72.00
INDEPENDENT CLAIMS	5 - 3 =	2	x 80.00	\$ 160.00
MULTIPLE DEPENDENT CLAIMS		N/A	\$270.00	
		TOTAL FEES	\$ 942.00	

METHOD OF PAYMENT

- Please charge Deposit Account No. 10-0750/ORT1453/RRP in the amount of \$942.00. Three copies of this sheet are enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT1453/RRP. Three copies of this sheet are enclosed.

SUBMITTED E	Complete (if applicable)		
Typed or Printed Name	Ralph/R. Palo		Reg. No. 29,486
Signature	hell All	Date: July 6, 2001	Deposit Account No. 10-0750

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Carlos Plata-Salaman and Jeffrey Crooke

FOR : ANTICONVULSANT DERIVATIVES USEFUL FOR PREVENTING THE

DEVELOPMENT OF TYPE II DIABETES MELLITUS AND

SYNDROME X

Express Mail Certificate

"Express Mail" mailing number: EL457891481US

Date of Deposit: July 6, 2001

I hereby certify that this complete application, including specification pages and claims is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

A Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

Karen Hall-Morgan

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)